Dade Behring consolidation means growth in 1998
This article was originally published in Clinica
Executive Summary
Dade Behring expects to achieve growth in both sales and operating income in 1998 as the full results of Behring - acquired last October - are included and as cost-cutting savings are implemented. The merger between the two diagnostics companies - Dade International and Behring Diagnostics - created the world's largest independent clinical chemistry company (see Clinica No 748, p 1).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.